Navigation Links
Treatment Combo for Pancreatic Cancer Has Limited Benefit
Date:3/4/2008

Chemo/chemoradiation therapy extended survival but not significantly

TUESDAY, March 4 (HealthDay News) -- In patients who had surgery for pancreatic cancer, adding the chemotherapy drug gemcitabine to chemoradiation prolonged survival, but the improvement was not statistically significant, a new study finds.

Among patients who have surgery to remove pancreatic cancer, there is a 50 percent to 85 percent rate of local relapse and a five-year survival rate of less than 20 percent, according to background information in the study.

This makes the combination of added postoperative chemotherapy and radiation an important consideration. Previous research has shown that gemcitabine is more effective than the drug fluorouracil at improving patient outcomes.

This study examined whether the addition of gemcitabine to the supplemental treatment of fluorouracil chemoradiation improved survival in patients who had a portion of their pancreas removed as a treatment for pancreatic cancer.

During the study, the 451 patients received either chemotherapy with gemcitabine (221) or with fluorouracil (230) for three weeks prior to chemoradiation therapy and for 12 weeks after chemoradiation therapy (with fluorouracil).

Among the 388 patients with pancreatic head tumors, those in the gemcitabine group had a median (midpoint) survival of 20.5 months and a three-year survival rate of 31 percent, compared to 16.9 months and 22 percent among those in the fluorouracil group. The rates of certain level (grade 4) of hematologic (abnormalities in blood cell counts) toxicity were 1 percent in the fluorouracil group and 14 percent in the gemcitabine group.

There were no differences in neutropenia (a blood disorder), infection, or in the ability to complete chemotherapy or radiation therapy.

"The addition of gemcitabine to (supplemental) fluorouracil-based chemoradiation was associated with a survival benefit for patients with resected pancreatic cancer, although this improvement was not statistically significant," the study authors concluded.

The study was published in the March 5 issue of the Journal of the American Medical Association.

More information

The American Cancer Society has more about pancreatic cancer.



-- Robert Preidt



SOURCE: Journal of the American Medical Association, news release, March 4, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. New potential drug target for the treatment of atherosclerosis
2. New Treatment for Lazy Eye Shows Promise
3. New target for cancer therapy may improve treatment for solid tumors
4. ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
5. Customized treatments for sepsis lower treatment time and reduce length of ICU stays
6. FDA Approves Luvox(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
7. Geriatric Oncology Consortium (GOC) Announces Tampa Bay Road Rally to Raise Awareness for the Treatment of Seniors With Cancer
8. Comparison of antipsychotic treatments in adolescents with schizophrenia
9. Treatment for disease that affects estimated 1 in 2000 children gets them to eat again
10. FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
11. Biomarkers for Mood May Alter Psychiatric Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... MA (PRWEB) , ... September 26, 2017 , ... CGL ... its first office under its new umbrella, CGL Technologies, LLC. , The new CGL ... industry veterans Remo Patitucci and Jon McCormack, both of whom have creative business development ...
(Date:9/26/2017)... Church, VA (PRWEB) , ... September 26, 2017 , ... ... and Cerulean Associates LLC **, Dec. 5-6, 2017 – Arlington, VA, http://www.fdanews.com/fdadataintegrity ... investigators: “If initial findings indicate the firm’s electronic records may not be trustworthy and ...
(Date:9/26/2017)... ... September 26, 2017 , ... DETECTO has been ... 1, 2017, the new agreement allows Premier members, at their discretion, to take ... “DETECTO is pleased to renew our agreement with Premier to be able to ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Sound of My Song”: ... the creation of published author, Karmen Worden, a retired teacher with a passion for ... book is an intriguing and inspiring story on loss, living with depression, and finding ...
(Date:9/26/2017)... ... ... Saves Boobie and Ceebie”: a tool families can use to teach children about the love ... author, G.S. White, a devoted follower of Jesus Chris who is married with one son. ... not only for children but also to glorified God in everything he does.” --G.S. White ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
(Date:9/6/2017)... 2017 NeuroRx, a clinical stage biopharma company developing ... (ASIB), has been granted Fast Track status by the US ... (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The company ... this sequential therapy targeting patients who are admitted to Emergency ... ...
(Date:9/5/2017)... another milestone in their continued growth and success of the company.  Xyntek has ... engagements regionally.  ... at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office will support the ... In addition to Xyntek,s headquarters ...
Breaking Medicine Technology: